Evaluation of the effect of Familact synbiotic on the outcomes of the patients with community acquired pneumonia (clinical improvement, laboratory and complications)

Determination of the effect of Familact synbiotic on the outcomes of the patients with community acquired pneumonia (clinical improvement, laboratory and complications)

Patients will be randomly divided into two groups using a random number table. One group will only be given antibiotics and the other group will be given antibiotics together with a capsule of synbiotic (Familact) daily for 10 days. All of the steps will be covered by the patient, physician and evaluators.

This prospective double-blind clinical trial study will be performed on the effect of Familact synbiotic in 130 patients over 18 years of age with community-acquired pneumonia admitted in the infectious ward of Vali-e-Asr Hospital in Birjand. Patients will be randomly divided into two groups using a random number table.

Inclusion criteria: Patients over 18 years old with community-acquired pneumonia diagnosed by an infectious disease specialist and requiring hospitalization (based on CURB-65 criteria), Patients with the same epidemiological factors (age, gender, and underlying disease) and possible microorganisms, Patients who need one type of treatment and do not need to other treatment such as steroids Exclusion criteria: Patients who have taken antibiotics 48 hours before hospitalization, Patients with immunodeficiency (HIV, receiving immunosuppressive drugs, transplantation, chemotherapy, acute pancreatitis), pregnant and lactating women, Patients who have consumed probiotics, prebiotics and synbiotics in the past month, Patients who have not consented

Intervention group: Familact capsule (once daily) for 10 days along with antibiotics Control group: Only antibiotics

Fever; Respiratory rate; WBC; ESR; CRP

Patients will be randomly divided into two groups using a random number table. In this way, first in Excel software, we create a variable from 1 to 130 (instead of 130, the total sample size). Then we create another variable in another column and generate 65 random numbers one and 65 random numbers two with the randomization command. The numbers of one are intervention group and the numbers of two groups are our placebo group.

The study is double-blind. The patient and the executor (student) are not aware of the type of treatment each person receives. The tablets are designed in the same shape and in the same shape as the cans. Numbers 1 to 130 are written on dark envelopes and type A or B is placed inside the envelope. Envelopes are such that they will not be visible from the outside. In order, each person who opens the envelope will be opened in order and based on the A or B treatment, a can of A or B tablets will be given to the patient along with an explanation of how to use it.